Y. Brewer

417 total citations
21 papers, 269 citations indexed

About

Y. Brewer is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Y. Brewer has authored 21 papers receiving a total of 269 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 5 papers in Surgery. Recurrent topics in Y. Brewer's work include Lung Cancer Diagnosis and Treatment (12 papers), Lung Cancer Treatments and Mutations (10 papers) and Lung Cancer Research Studies (6 papers). Y. Brewer is often cited by papers focused on Lung Cancer Diagnosis and Treatment (12 papers), Lung Cancer Treatments and Mutations (10 papers) and Lung Cancer Research Studies (6 papers). Y. Brewer collaborates with scholars based in France, United States and Monaco. Y. Brewer's co-authors include F Reboul, B. Chauvet, P Vincent, Pascal Vincent, R. Garcia, Jean‐Louis Davin, Sylvie Kirscher, Claire Faure, Laurent Zelek and Daniel Martín and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Journal of Urology.

In The Last Decade

Y. Brewer

21 papers receiving 260 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Y. Brewer France 9 167 111 95 24 21 21 269
Bagshaw Ma United States 9 271 1.6× 79 0.7× 101 1.1× 19 0.8× 6 0.3× 22 403
P. Chan United States 7 66 0.4× 125 1.1× 243 2.6× 32 1.3× 25 1.2× 14 360
Enrico Sarti Italy 10 215 1.3× 348 3.1× 355 3.7× 98 4.1× 24 1.1× 14 580
K.R. Durrant United Kingdom 7 103 0.6× 129 1.2× 85 0.9× 11 0.5× 18 0.9× 14 279
Jerold P. Green United States 9 108 0.6× 70 0.6× 179 1.9× 32 1.3× 17 0.8× 16 245
Prasert Lertsanguansinchai Thailand 9 86 0.5× 102 0.9× 195 2.1× 20 0.8× 16 0.8× 22 370
Louis F. Jacques Canada 8 399 2.4× 199 1.8× 136 1.4× 27 1.1× 8 0.4× 10 500
Monica Lo Russo Italy 10 127 0.8× 45 0.4× 61 0.6× 22 0.9× 40 1.9× 24 276
Sophie Otter United Kingdom 10 75 0.4× 88 0.8× 73 0.8× 31 1.3× 3 0.1× 22 287
Marketa Skala Australia 13 278 1.7× 54 0.5× 62 0.7× 13 0.5× 27 1.3× 23 392

Countries citing papers authored by Y. Brewer

Since Specialization
Citations

This map shows the geographic impact of Y. Brewer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Y. Brewer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Y. Brewer more than expected).

Fields of papers citing papers by Y. Brewer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Y. Brewer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Y. Brewer. The network helps show where Y. Brewer may publish in the future.

Co-authorship network of co-authors of Y. Brewer

This figure shows the co-authorship network connecting the top 25 collaborators of Y. Brewer. A scholar is included among the top collaborators of Y. Brewer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Y. Brewer. Y. Brewer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pierga, Jean‐Yves, P. Fumoleau, Y. Brewer, et al.. (2004). Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program. Breast Cancer Research and Treatment. 88(2). 117–129. 27 indexed citations
2.
Braud, Anne‐Chantal, et al.. (2003). Direct Treatment Costs for Patients with Lung Cancer from First Recurrence to Death in France. PharmacoEconomics. 21(9). 671–679. 24 indexed citations
3.
4.
Chauvet, B., et al.. (1998). High dose rate endobronchial brachytherapy: results and complications in 189 patients. European Respiratory Journal. 11(1). 162–168. 62 indexed citations
5.
Berger, Christine, Sylvie Kirscher, B. Chauvet, et al.. (1998). Radiochimiothérapie concomitante préopératoire pour cancer du rectum. Cancer/Radiothérapie. 2(3). 260–265. 5 indexed citations
6.
Reboul, F, et al.. (1997). Radio-chimiothérapie concomitante dans les cancers bronchiques localement évolués: résultats actuels et perspectives. Cancer/Radiothérapie. 1(2). 113–120. 2 indexed citations
7.
8.
9.
Serin, Daniel, Sylvie Kirscher, Y. Brewer, et al.. (1997). [Adjuvant combined radiochemotherapy: a feasibility study of a new strategy in stages I and II].. PubMed. 84(3). 247–53. 9 indexed citations
10.
Reboul, F, et al.. (1996). Concurrent cisplatin, etoposide, and radiotherapy for unresectable Stage III nonsmall cell lung cancer: A Phase II study. International Journal of Radiation Oncology*Biology*Physics. 35(2). 343–350. 26 indexed citations
11.
Chauvet, B., et al.. (1996). Concurrent Cisplatin and Radiotherapy for Patients with Muscle Invasive Bladder Cancer Who are not Candidates for Radical Cystectomy. The Journal of Urology. 1258–1262. 2 indexed citations
12.
Reboul, F, et al.. (1996). [Preoperative radio-chemotherapy of stage III unresectable non-small cell lung cancer: results of a pilot study].. PubMed. 83(4). 300–6. 4 indexed citations
13.
Vincent, P, B. Chauvet, D. Serin, et al.. (1996). Associations radiothérapie-chimiothérapie dans les cancers du col utérin localement évolués. PubMed. 83(4). 377–384. 1 indexed citations
14.
Reboul, F, et al.. (1995). [Radiotherapy and concomitant cisplatin in stage III non-small cell bronchial cancer: results of a pilot study].. PubMed. 82(3). 196–201. 1 indexed citations
15.
Reboul, F, et al.. (1995). [Stage III non-small cell lung cancers: prospects of concomitant radiochemotherapy].. PubMed. 82(1). 28–34. 1 indexed citations
16.
17.
Chauvet, B., et al.. (1994). Prostate-specific antigen decline: a major prognostic factor for prostate cancer treated with radiation therapy.. Journal of Clinical Oncology. 12(7). 1402–1407. 34 indexed citations
18.
Reboul, F, et al.. (1994). Radiation therapy with concomitant continuous infusion cisplatin for unresectable nonsmall cell lung carcinoma. International Journal of Radiation Oncology*Biology*Physics. 28(5). 1251–1256. 9 indexed citations
19.
Chauvet, B., et al.. (1993). Combined radiation therapy and cisplatin for locally advanced carcinoma of the urinary bladder. Cancer. 72(7). 2213–2218. 10 indexed citations
20.
Chauvet, B., et al.. (1993). [Treatment of obstructive bronchial cancers with high dose, endobronchial curietherapy. Technical aspects and clinical results].. PubMed. 10(4). 347–51. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bagshaw Ma Breakdown of academic impact, for papers by P. Chan Breakdown of academic impact, for papers by Enrico Sarti Breakdown of academic impact, for papers by K.R. Durrant Breakdown of academic impact, for papers by Jerold P. Green Breakdown of academic impact, for papers by Prasert Lertsanguansinchai Breakdown of academic impact, for papers by Louis F. Jacques Breakdown of academic impact, for papers by Monica Lo Russo Breakdown of academic impact, for papers by Sophie Otter Breakdown of academic impact, for papers by Marketa Skala
Rankless by CCL
2026